Puma Biotechnology, Inc. (NASDAQ:PBYI) traded at $11.16 at last check on Friday, Nov 20, making an upward move of 10.82% on its previous day’s price.
Looking at the stock we see that its previous close was $10.07 and the beta (5Y monthly) reads 1.16 with the day’s price range being $9.90 – 11.28. The company has a 12-month trailing PE ratio of 0. In terms of its 52-week price range, PBYI has a high of $15 and a low of $5.5. The company’s stock has gained about 17.72% over that past 30 days.
Puma has a market cap of $436.8 Million and is expected to release its quarterly earnings report on Feb 18, 2021- Feb 22, 2021. With its Forward Dividend at 0 and a yield of 0%, the company’s investors could be worried for the PBYI stock to lose ahead of the earnings release. Estimates by analysts give the company expected earnings per share (EPS) of -$0.3, with the EPS growth for the year raised at -$1.38 for 2020 and -$1.01 for next year. These figures represent -0.29% and at -0.27% growth in EPS for the two years respectively.
Analysts tracking the company’s growth have also given it a consensus growth in revenue estimated at $53.19 Million, with a low of $50.98 Million and a high of $58.75 Million. The median projection represents growth adding up to -15.4% compared to sales earnings for the corresponding quarter a year ago. According to analyst consensus estimates figures, the company’s yearly revenue forecasts for 2020 are expected to hit $225.68 Million, or -17.1% down from figures reported last year.
There have been 2 upward and no downward revisions for the stock’s EPS in last 7 days, something that reflects the nature of company’s price movement in short term. On the other hand, looking at the outlook for the PBYI stock, short term indicators assign the stock an average of 50% Sell, while medium term indicators assign it an average of 50% Sell. Long term indicators on average place the stock in the category of 50% Buy.
Based on estimates by 8 analysts where scores have ranged from 1.00 for a strong buy to 5.00 for a strong sell, 3 have rated the Puma Biotechnology, Inc. (PBYI) stock as a Hold, while 1 rate it as a Buy. None analysts rate it as outperform while 1 of them rated it as underperform, whereas 3 suggests the stock as a Sell. The stock has an overall rating of Underweight and investors could take advantage and scoop up stock of the company.
Looking further, we note that the PEG ratio for the PBYI stock currently stands at 0, and the current price level is 25.69% off its SMA20 and 17.39% from its 50-day simple moving average. The RSI (14) is pointing at 72.2 while the volatility over the past week is 7.67% and drops to 6.83% over the past one month. The beta value is 1.16, while the average true range (ATR) is currently pointing at 0.6. The average price target for the stock over the next 12 months is $9.14, with the estimates having a low of $6 and a high of $15. These price ends are -46.24% and +34.41% off the current price level respectively, although investors could be excited at the prospect of a -19.35% if the PBYI share price touches on the median price of $9.
Let’s briefly compare Puma (PBYI) stock to its peers. We find that today’s price change of +10.82% and +25.25% over the past 12 months for PBYI betters that of Bristol-Myers Squibb Company (BMY), which has seen its stock price fall -0.77% in the latest trading session and is +8.37% over the last one year. Another of its peers Amgen Inc (AMGN) has dropped -0.67% today, but is -2.04% down over the past year, while Gilead Sciences Inc (GILD) is also up 10.82% yet its price remains in the green at 25.25% over the same period. Bristol-Myers has a P/E ratio of 0 compared to Puma’s 0 and Amgen’s 17.99. In contrast to these companies, both the S&P 500 Index and the Dow Jones Industrial are today at -0.68% and -0.75%, respectively, in early deals.
Coming back to Puma Biotechnology, Inc. (NASDAQ:PBYI), we note that the average 3-month trading volume was 570.99 Million, while that of the preceding 10-day period stands at 435.76 Million. Current shares outstanding are 39.76 Million.
According to data from Thomson Reuters, insiders hold 13.47% of the company’s shares while institutions hold 95.45%. The data shows that short shares as of October 29, 2020, stood at 8Million at a short ratio of 15.26. This represents a 20.11% Short interest in Shares outstanding on October 29, 2020. Shares short rose in October from the previous month at 7.27 Million. Investors should be excited about this stock as its upside potential is great, with today’s price pushing the stock +27.54% up in year-to-date price movement.